

# Iain B Mcinnes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9312059/publications.pdf>

Version: 2024-02-01

100  
papers

20,181  
citations

32410

55  
h-index

38517

99  
g-index

101  
all docs

101  
docs citations

101  
times ranked

20418  
citing authors

#	ARTICLE	IF	CITATIONS
1	Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. <i>Modern Rheumatology</i> , 2022, 32, 1-11.	0.9	21
2	Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 475-485.	2.9	41
3	Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 359-369.	0.5	47
4	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. <i>RMD Open</i> , 2022, 8, e002195.	1.8	11
5	Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1184-1192.	2.9	5
6	Psoriatic arthritis from a mechanistic perspective. <i>Nature Reviews Rheumatology</i> , 2022, 18, 311-325.	3.5	49
7	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.5	158
8	Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 604-616.	2.9	48
9	Tendinopathy. <i>Nature Reviews Disease Primers</i> , 2021, 7, 1.	18.1	388
10	Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2021, 384, 1227-1239.	13.9	143
11	Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. <i>Rheumatology</i> , 2021, 60, 5337-5350.	0.9	18
12	Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e337-e346.	2.2	24
13	Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. <i>RMD Open</i> , 2021, 7, e001679.	1.8	19
14	Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1494-1497.	0.5	33
15	Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1815-1823.	1.0	20
16	Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. <i>Rheumatology</i> , 2021, 60, 2109-2121.	0.9	44
17	COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes. <i>JCI Insight</i> , 2021, 6, .	2.3	35
18	BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study. <i>BMC Rheumatology</i> , 2021, 5, 22.	0.6	4

#	ARTICLE	IF	CITATIONS
19	The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 941-952.	1.5	9
20	Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. <i>New England Journal of Medicine</i> , 2021, 385, 628-639.	13.9	156
21	Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. <i>Nature Reviews Rheumatology</i> , 2021, 17, 585-595.	3.5	99
22	Translational targeting of inflammation and fibrosis in frozen shoulder: Molecular dissection of the T cell/IL-17A axis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	18
23	Immune-mediated inflammatory disease therapeutics: past, present and future. <i>Nature Reviews Immunology</i> , 2021, 21, 680-686.	10.6	106
24	Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. <i>RMD Open</i> , 2021, 7, e001838.	1.8	42
25	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e001845.	1.8	11
26	Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. <i>British Journal of Dermatology</i> , 2020, 182, 130-137.	1.4	52
27	JAK inhibitors and infections risk: focus on herpes zoster. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093605.	1.2	72
28	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020, 6, e001374.	1.8	36
29	Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with demographic, socioeconomic and disease features. <i>RMD Open</i> , 2020, 6, e001376.	1.8	31
30	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. <i>Lancet, The</i> , 2020, 395, 1496-1505.	6.3	178
31	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.5	609
32	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 760-770.	0.5	205
33	Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1126-1136.	6.3	206
34	Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. <i>Nature Medicine</i> , 2020, 26, 1295-1306.	15.2	304
35	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020, 395, 427-440.	6.3	122
36	Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 193-207.	3.5	122

#	ARTICLE	IF	CITATIONS
37	Reflections on “older” drugs: learning new lessons in rheumatology. <i>Nature Reviews Rheumatology</i> , 2020, 16, 179-183.	3.5	13
38	Immunoglobulin A antibodies to oxidized collagen type II as a potential biomarker for the stratification of spondyloarthritis from rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 281-291.	0.6	5
39	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019, 20, 429.	0.7	77
40	Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. <i>Nature Reviews Rheumatology</i> , 2019, 15, 461-474.	3.5	95
41	Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. <i>Cell Reports</i> , 2019, 28, 2455-2470.e5.	2.9	241
42	Europe rules on harm from fluoroquinolone antibiotics. <i>Nature</i> , 2019, 566, 326-326.	13.7	12
43	Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. <i>PLoS Medicine</i> , 2019, 16, e1002739.	3.9	144
44	Tranexamic acid toxicity in human periarticular tissues. <i>Bone and Joint Research</i> , 2019, 8, 11-18.	1.3	56
45	Responsiveness of Serum C-reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-blind, Placebo-controlled Trials. <i>Arthritis and Rheumatology</i> , 2019, 71, 1660-1669.	2.9	13
46	Clinical applications of machine learning algorithms: beyond the black box. <i>BMJ: British Medical Journal</i> , 2019, 364, l886.	2.4	213
47	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 761-772.	0.5	219
48	Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naïve Patients from 2 Phase III Ustekinumab Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1458-1461.	1.0	11
49	S100A8 & S100A9: Alarmin mediated inflammation in tendinopathy. <i>Scientific Reports</i> , 2019, 9, 1463.	1.6	61
50	OP0114...MACHINE LEARNING TOOLS IDENTIFY PATIENT CLUSTERS AND SWOLLEN AND TENDER JOINT CORRELATION PATTERNS IN A LARGE DATABASE FROM THE SECUKINUMAB PSORIATIC ARTHRITIS CLINICAL DEVELOPMENT PROGRAM. , 2019, , .		1
51	Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1642-1652.	0.5	85
52	Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. <i>RMD Open</i> , 2019, 5, e000990.	1.8	17
53	Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1015-1018.	0.5	77
54	Rheumatoid arthritis and depression: an inflammatory perspective. <i>Lancet Psychiatry</i> , 2019, 6, 164-173.	3.7	238

#	ARTICLE	IF	CITATIONS
55	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18001.	18.1	1,441
56	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). <i>Arthritis Research and Therapy</i> , 2018, 20, 47.	1.6	117
57	Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. <i>Arthritis Research and Therapy</i> , 2018, 20, 113.	1.6	24
58	Inflammatory mechanisms in tendinopathy – towards translation. <i>Nature Reviews Rheumatology</i> , 2017, 13, 110-122.	3.5	269
59	A randomised phase IIb study of mavrimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1020-1030.	0.5	117
60	Immunopathogenesis of Rheumatoid Arthritis. <i>Immunity</i> , 2017, 46, 183-196.	6.6	780
61	Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation <i>in Vitro</i> . <i>Journal of Rheumatology</i> , 2017, 44, 748-756.	1.0	22
62	Managing rheumatic and musculoskeletal diseases – past, present and future. <i>Nature Reviews Rheumatology</i> , 2017, 13, 443-448.	3.5	117
63	Pathogenetic insights from the treatment of rheumatoid arthritis. <i>Lancet, The</i> , 2017, 389, 2328-2337.	6.3	942
64	EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 17-28.	0.5	918
65	Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1949-1952.	0.5	63
66	Targeting danger molecules in tendinopathy: the HMGB1/TLR4 axis. <i>RMD Open</i> , 2017, 3, e000456.	1.8	33
67	MicroRNA29a Treatment Improves Early Tendon Injury. <i>Molecular Therapy</i> , 2017, 25, 2415-2426.	3.7	51
68	Synovial tissue research: a state-of-the-art review. <i>Nature Reviews Rheumatology</i> , 2017, 13, 463-475.	3.5	175
69	Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis. <i>Atherosclerosis</i> , 2016, 254, 167-171.	0.4	20
70	Brief Report: Proatherogenic Cytokine Microenvironment in the Aortic Adventitia of Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1361-1366.	2.9	27
71	IL-17A mediates inflammatory and tissue remodelling events in early human tendinopathy. <i>Scientific Reports</i> , 2016, 6, 27149.	1.6	89
72	MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12970.	5.8	97

#	ARTICLE	IF	CITATIONS
73	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 461.	0.8	22
74	Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. <i>Journal of Rheumatology</i> , 2016, 43, 1713-1717.	1.0	77
75	Brief Report: Predicting Functional Disability: One-Year Results From the Scottish Early Rheumatoid Arthritis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2016, 68, 1596-1602.	2.9	29
76	Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1806-1812.	0.5	119
77	Mast Cells Contribute to <i>Porphyromonas gingivalis</i> -induced Bone Loss. <i>Journal of Dental Research</i> , 2016, 95, 704-710.	2.5	25
78	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 499-510.	0.5	743
79	Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1739-1749.	1.5	87
80	Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 694-702.	0.5	237
81	The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention. <i>Annual Review of Medicine</i> , 2015, 66, 311-328.	5.0	1,074
82	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2015, 386, 1137-1146.	6.3	722
83	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2015, 373, 1329-1339.	13.9	629
84	MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease. <i>Nature Communications</i> , 2015, 6, 6774.	5.8	141
85	Small-molecule therapeutics in rheumatoid arthritis: Scientific rationale, efficacy and safety. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 605-624.	1.4	32
86	Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 990-999.	0.5	576
87	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 62-68.	0.5	659
88	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. <i>Lancet</i> , The, 2013, 382, 780-789.	6.3	688
89	Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 211-216.	0.5	224
90	Alarmins in tendinopathy: unravelling new mechanisms in a common disease. <i>Rheumatology</i> , 2013, 52, 769-779.	0.9	48

#	ARTICLE	IF	CITATIONS
91	How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy. <i>Nature Medicine</i> , 2013, 19, 822-824.	15.2	341
92	Hypoxia: a critical regulator of early human tendinopathy. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 302-310.	0.5	118
93	MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 11193-11198.	3.3	644
94	State-of-the-art: rheumatoid arthritis: Figure 1. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1898-1906.	0.5	268
95	Tumour necrosis factor $\alpha$ blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1281-1285.	0.5	53
96	Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1251-1252.	0.5	28
97	Inflammation is Present in Early Human Tendinopathy. <i>American Journal of Sports Medicine</i> , 2010, 38, 2085-2091.	1.9	241
98	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	0.5	1,711
99	Role for TNF in atherosclerosis? Lessons from autoimmune disease. <i>Nature Reviews Cardiology</i> , 2009, 6, 410-417.	6.1	252
100	New strategies to control inflammatory synovitis: interleukin 15 and beyond. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 51ii-54.	0.5	25